Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Apogenix (Germany) a clinical-stage biopharmaceutical company focused on modulators of apoptosis and IL-4 signaling for glioblastoma and other cancers, graft versus host disease and inflammatory diseases, closed a $10M Series C financing. Participants include Dievini Hopp BioTech.

TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage small molecule company focused on apoptosis and necrosis modulation for potential cancer, cardiovascular, neurological and ophthalmic disease treatment, closed a $5M Series C financing, bringing the total round to $37M. Participants include Pfizer Venture Investments, Clarus Ventures, Hatteras Venture Partners, Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, […]

TetraLogic Pharmaceuticals (Malvern, PA) a preclinical-stage small molecule company focused on apoptosis and necrosis modulation for potential cancer, cardiovascular, neurological and ophthalmic disease treatment, closed a $32M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and Vertical Group.

Gemin X Pharmaceuticals (Canada) a clinical-stage biopharmaceutical company developing focused on modulating apoptotic therapeutics for hematological and solid tumors, including chronic lymphocytic leukemia, melanoma, small cell lung cancer, lymphoma, myeloma and glioblastoma multiforme, closed a $16M Series D financing. Participants include Caxton Advantage Life Sciences Fund and Sanderling Ventures.

Apoptos (San Diego, CA) developer of small molecule oncology therapeutics that activate apoptosis, closed a $28M Series B financing. Participants include Venrock, ARCH Venture Partners, OrbiMed Advisors, and Advanced Technology Ventures.

Apogenix (Germany) development-stage biopharmaceutical company focused on targeted modulation of apoptosis, closed a $44M Series B financing. Participants include Dievini Hopp BioTech Holdings.

  

to top of page...